| Source : |
HEK293 |
| Species : |
Human |
| Tag : |
hFc |
| Form : |
Lyophilized from sterile PBS, pH 7.4Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA. |
| Bio-activity : |
1. Immobilized Human VEGF121 at 2 μg/mL (100 μL/well) can bind Human VEGFR2/KDR (ECD, hFc Tag), the EC50 of Human VEGFR2/KDR (ECD, hFc Tag) is 6-48 ng/mL.2. Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 20-120 ng/mL in the presence of 10 ng/mL recombinant human VEGF165. |
| Molecular Mass : |
The recombinant human VEGFR2/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 979 amino acids and predicts a molecular mass of 109 kDa. The apparent molecular mass of human VEGFR2/Fc monomer is approximatly 150-160 KDa in SDS-PAGE under reducing conditions due to glycosylation. |
| Proteinlength : |
Met1-Glu764 |
| Endotoxin : |
< 1.0 EU per μg of the protein as determined by the LAL method |
| Purity : |
> 90 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC. |
| Storage : |
Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Reconstitution : |
It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents. |
